Last $4.13 USD
Change Today -0.02 / -0.48%
Volume 1.2M
SNTA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

synta pharmaceuticals corp (SNTA) Snapshot

Open
$4.15
Previous Close
$4.15
Day High
$4.19
Day Low
$4.08
52 Week High
07/30/13 - $7.85
52 Week Low
11/13/13 - $3.70
Market Cap
385.2M
Average Volume 10 Days
1.5M
EPS TTM
$-1.25
Shares Outstanding
93.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNTA PHARMACEUTICALS CORP (SNTA)

synta pharmaceuticals corp (SNTA) Related Businessweek News

No Related Businessweek News Found

synta pharmaceuticals corp (SNTA) Details

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its lead drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; and in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer. The company’s product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; and Elesclomol, a mitochondria-targeting agent that is in Phase 2 clinical trial for ovarian cancer. Its product pipeline in preclinical development stage for inflammatory diseases includes CRACM ion channel inhibitors for rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergy, transplant rejection, and other autoimmune diseases and inflammatory conditions; and IL-12/23 inhibitors for inflammatory and autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.

134 Employees
Last Reported Date: 03/11/14
Founded in 2000

synta pharmaceuticals corp (SNTA) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $349.7K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $486.3K
Vice President of Intellectual Property & Leg...
Total Annual Compensation: $353.6K
Compensation as of Fiscal Year 2013.

synta pharmaceuticals corp (SNTA) Key Developments

Synta Pharmaceuticals Corp. Announces Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Study for Patients with AML and High-Risk MDS

Synta Pharmaceuticals Corp. announced the advancement of ganetespib into the Phase 3 extension of the AML LI-1 (less intensive) trial. AML LI-1 is a multicenter, randomized Phase 2/3 clinical study evaluating several novel treatment regimens, including the combination of ganetespib with low dose cytarabine (Ara-C), in newly diagnosed elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are not eligible for intensive chemotherapy. Ganetespib is a next-generation inhibitor of the chaperone protein Hsp90, which is critical for the activation and stability of numerous proteins that drive cancer growth and proliferation. Ganetespib has been studied in over 1,000 patients to date. Advancement into the Phase 3 extension follows an interim analysis of results from 50 patients who received the ganetespib-cytarabine combination in the Phase 2 portion of the trial. The primary efficacy outcome in Phase 2 was rate of complete response. Per protocol, the Phase 3 extension will include an interim futility analysis and enroll approximately 200 patients in the ganetespib-cytarabine and the cytarabine alone arms, for a total of approximately 400 patients. The primary efficacy endpoint for the Phase 3 extension will include overall survival. The Company is currently in discussion with study investigators, and anticipates providing additional details, including the timing of study milestones, as they become formalized. The AML LI-1 trial is the first of three multicenter, randomized studies supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK to include a ganetespib treatment arm. AML LI-1 is being conducted under the auspices of the UK's National Cancer Research Institute (NCRI) Haematological Oncology Study Group, with investigators in Denmark, France, New Zealand, and the UK, and under the sponsorship of Cardiff University, UK. The other two studies, to be initiated later this year, are the AML-18 trial, evaluating ganetespib with standard DA (daunorubin and Ara-C) in patients over 60 years old who can tolerate intensive chemotherapy, and the AML-19 trial, evaluating ganetespib in combination with conventional chemotherapy in younger patients with AML.

Synta Pharmaceuticals Corp. Terminates Steven Bernitz, Senior Vice President, Corporate Development

On June 23, 2014, Synta Pharmaceuticals Corp. notified Steven Bernitz, Senior Vice President, Corporate Development, that his employment with the company was being terminated effective as of June 27, 2014.

Synta Pharmaceuticals Corp. Presents at JMP Securities Healthcare Conference, Jun-25-2014 02:30 PM

Synta Pharmaceuticals Corp. Presents at JMP Securities Healthcare Conference, Jun-25-2014 02:30 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNTA:US $4.13 USD -0.02

SNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNTA.
View Industry Companies
 

Industry Analysis

SNTA

Industry Average

Valuation SNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNTA PHARMACEUTICALS CORP, please visit www.syntapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.